Inhaled corticosteroids for stable chronic obstructive pulmonary disease

IA Yang, MS Clarke, EHA Sim… - Cochrane Database of …, 2012 - cochranelibrary.com
Background The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary
disease (COPD) has been the subject of much controversy. Major international guidelines …

How inhaled corticosteroids target inflammation in COPD

S Lea, A Higham, A Beech… - European Respiratory …, 2023 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) are the most commonly used anti-inflammatory drugs for the
treatment of COPD. COPD has been previously described as a “corticosteroid-resistant” …

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

C Crim, PMA Calverley, JA Anderson… - European …, 2009 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated
with chronic obstructive pulmonary disease (COPD). However, little is known about the risk …

Oxidative stress and airway inflammation in severe exacerbations of COPD

EM Drost, KM Skwarski, J Sauleda, N Soler, J Roca… - Thorax, 2005 - thorax.bmj.com
Background: A study was undertaken to assess both oxidative stress and inflammation in the
lungs of patients with chronic obstructive pulmonary disease (COPD) during severe and very …

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

CE Brightling, S McKenna, B Hargadon, S Birring… - Thorax, 2005 - thorax.bmj.com
Background: An association between the sputum eosinophil count and the response to a 2
week course of prednisolone has previously been reported in patients with chronic …

Contemporary management of chronic obstructive pulmonary disease: scientific review

DD Sin, FA McAlister, SFP Man, NR Anthonisen - Jama, 2003 - jamanetwork.com
Context The care of patients with chronic obstructive pulmonary disease (COPD) has
changed radically over the past 2 decades, and novel therapies can not only improve the …

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

DA Mahler, P Wire, D Horstman, CN Chang… - American journal of …, 2002 - atsjournals.org
This randomized controlled trial examined the benefits of combining an inhaled
corticosteroid, fluticasone propionate (F), with an inhaled long-acting β2-agonist, salmeterol …

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

P Kardos, M Wencker, T Glaab… - American journal of …, 2007 - atsjournals.org
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) greatly
contribute to declining health status and the progression of the disease, thereby incurring …

Eosinophilic airway inflammation in COPD

S Saha, CE Brightling - International journal of chronic obstructive …, 2006 - Taylor & Francis
Chronic obstructive pulmonary disease is a common condition and a major cause of
mortality. COPD is characterized by irreversible airflow obstruction. The physiological …

The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD

NA Hanania, P Darken, D Horstman, C Reisner, B Lee… - Chest, 2003 - Elsevier
Study objectives: To compare the efficacy and safety of the inhaled corticosteroid fluticasone
propionate (FP) and the inhaled long-acting β 2-agonist salmeterol (SM), when administered …